MPNs

The FDA has granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.<br /> &nbsp;

Aziz Nazha, MD, discusses the different agents being explored for patients who have progressed on ruxolitinib, and why this is a significant unmet need. He also highlights the role of genetics in patients with MF and how a better understanding can help guide treatment decisions.

Robyn M. Scherber, MD, MPH, discusses her advice for treating patients with myelofibrosis that become refractory or resistant to ruxolitinib.

Rami S. Komrokji, MD, explains the diagnostic and molecular workup behind myeloproliferative neoplasm diagnoses and discusses treatment options based on the case scenario of a patient with myelofibrosis.

Raajit K. Rampal, MD, PhD,&nbsp;discusses a retrospective analysis of pre-transplant samples from patients with MF to determine the value of mutational profiling in predicting outcomes after transplant.

A new report published in<em> Leukemia Research</em> found that results from the lead-in cohort of an open-label phase lb/II trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with at least 1 JAK inhibitor indicated acceptable safety and tolerability.

A 58-Year-Old Woman with Polycythemia Vera

JAK Inhibition for the Management of Primary Myelofibrosis